Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Detailed Characterization of Mesenchymal Stem/Stromal Cells from a Large Cohort of AML Patients Demonstrates a Definitive Link to Treatment Outcomes.
Diaz de la Guardia R, Lopez-Millan B, Lavoie JR, Bueno C, Castaño J, Gómez-Casares M, Vives S, Palomo L, Juan M, Delgado J, Blanco ML, Nomdedeu J, Chaparro A, Fuster JL, Anguita E, Rosu-Myles M, Menéndez P. Diaz de la Guardia R, et al. Stem Cell Reports. 2017 Jun 6;8(6):1573-1586. doi: 10.1016/j.stemcr.2017.04.019. Epub 2017 May 18. Stem Cell Reports. 2017. PMID: 28528702 Free PMC article.
Bone marrow mesenchymal stem/stromal cells from risk-stratified acute myeloid leukemia patients are anti-inflammatory in in vivo preclinical models of hematopoietic reconstitution and severe colitis.
de la Guardia RD, Lopez-Millan B, Roca-Ho H, Bueno C, Gutiérrez-Agüera F, Fuster JL, Anguita E, Zanetti SR, Vives S, Nomdedeu J, Sackstein R, Lavoie J, Gónzalez-Rey E, Delgado M, Rosu-Myles M, Menendez P. de la Guardia RD, et al. Among authors: lopez millan b. Haematologica. 2019 Feb;104(2):e54-e58. doi: 10.3324/haematol.2018.196568. Epub 2018 Sep 20. Haematologica. 2019. PMID: 30237260 Free PMC article. No abstract available.
Bone Marrow Clonogenic Myeloid Progenitors from NPM1-Mutated AML Patients Do Not Harbor the NPM1 Mutation: Implication for the Cell-Of-Origin of NPM1+ AML.
Guardia RD, González-Silva L, López-Millán B, Rodríguez-Sevilla JJ, Baroni ML, Bueno C, Anguita E, Vives S, Palomo L, Lapillonne H, Varela I, Menendez P. Guardia RD, et al. Among authors: lopez millan b. Genes (Basel). 2020 Jan 9;11(1):73. doi: 10.3390/genes11010073. Genes (Basel). 2020. PMID: 31936647 Free PMC article.
Engraftment characterization of risk-stratified AML in NSGS mice.
Díaz de la Guardia R, Velasco-Hernandez T, Gutiérrez-Agüera F, Roca-Ho H, Molina O, Nombela-Arrieta C, Bataller A, Fuster JL, Anguita E, Vives S, Zamora L, Nomdedeu J, Gómez-Casares MT, Ramírez-Orellana M, Lapillonne H, Ramos-Mejia V, Rodríguez-Manzaneque JC, Bueno C, Lopez-Millan B, Menéndez P. Díaz de la Guardia R, et al. Among authors: lopez millan b. Blood Adv. 2021 Dec 14;5(23):4842-4854. doi: 10.1182/bloodadvances.2020003958. Blood Adv. 2021. PMID: 34470043 Free PMC article.
IMiDs mobilize acute myeloid leukemia blasts to peripheral blood through downregulation of CXCR4 but fail to potentiate AraC/Idarubicin activity in preclinical models of non del5q/5q- AML.
Lopez-Millan B, Diaz de la Guardia R, Roca-Ho H, Anguita E, Islam ABMMK, Romero-Moya D, Prieto C, Gutierrez-Agüera F, Bejarano-Garcia JA, Perez-Simon JA, Costales P, Rovira M, Marín P, Menendez S, Iglesias M, Fuster JL, Urbano-Ispizua A, Anjos-Afonso F, Bueno C, Menendez P. Lopez-Millan B, et al. Oncoimmunology. 2018 Jul 26;7(9):e1477460. doi: 10.1080/2162402X.2018.1477460. eCollection 2018. Oncoimmunology. 2018. PMID: 30228947 Free PMC article.
Robust In Vitro and In Vivo Immunosuppressive and Anti-inflammatory Properties of Inducible Caspase-9-mediated Apoptotic Mesenchymal Stromal/Stem Cell.
Romecín PA, Vinyoles M, López-Millán B, de la Guardia RD, Atucha NM, Querol S, Bueno C, Benitez R, Gonzalez-Rey E, Delgado M, Menéndez P. Romecín PA, et al. Among authors: lopez millan b. Stem Cells Transl Med. 2022 Mar 3;11(1):88-96. doi: 10.1093/stcltm/szab007. Stem Cells Transl Med. 2022. PMID: 35641173 Free PMC article.
NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia.
Lopez-Millan B, Sanchéz-Martínez D, Roca-Ho H, Gutiérrez-Agüera F, Molina O, Diaz de la Guardia R, Torres-Ruiz R, Fuster JL, Ballerini P, Suessbier U, Nombela-Arrieta C, Bueno C, Menéndez P. Lopez-Millan B, et al. Leukemia. 2019 Jul;33(7):1557-1569. doi: 10.1038/s41375-018-0353-0. Epub 2019 Jan 11. Leukemia. 2019. PMID: 30635633 Free PMC article.
17 results